| |
| |
|
| Insider
Information: |
Sachdev Amit |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
71,325 |
|
|
Indirect Shares
|
7,447 |
|
|
| Direct
Value |
$26,276,609 |
|
|
|
Indirect Value
|
$3,536,953 |
|
|
| Total
Shares |
78,772 |
|
|
| Total
Value |
$29,813,561 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP Chief Patient & Ex... |
2024-05-15 |
55,325 |
2024-05-15 |
7,447 |
Premium* |
|
|
Celladon Corp |
CLDN |
|
2022-03-11 |
16,000 |
2020-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-23 |
4 |
D |
$431.79 |
$1,066,090 |
D/D |
(2,469) |
58,329 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-05-15 |
4 |
AS |
$430.93 |
$13,790 |
D/D |
(32) |
55,325 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-26 |
4 |
AS |
$425.70 |
$1,278,803 |
D/D |
(3,004) |
55,325 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-16 |
4 |
D |
$424.01 |
$1,483,187 |
D/D |
(3,498) |
70,866 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-09 |
4 |
D |
$422.74 |
$854,780 |
D/D |
(2,022) |
77,586 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-21 |
4 |
AS |
$421.77 |
$1,345,868 |
D/D |
(3,191) |
60,798 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-20 |
4 |
AS |
$420.79 |
$1,790,041 |
D/D |
(4,254) |
63,989 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-20 |
4 |
D |
$420.58 |
$1,103,181 |
D/D |
(2,623) |
68,243 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-12 |
4 |
AS |
$420.24 |
$1,354,013 |
D/D |
(3,222) |
74,364 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2023-11-15 |
4 |
AS |
$369.92 |
$12,947 |
D/D |
(35) |
58,814 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2023-08-10 |
4 |
AS |
$350.00 |
$3,510,850 |
D/D |
(10,031) |
58,814 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2023-02-13 |
4 |
D |
$298.26 |
$1,388,997 |
D/D |
(4,657) |
72,484 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2023-02-10 |
4 |
D |
$294.33 |
$768,496 |
D/D |
(2,611) |
77,141 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2023-02-17 |
4 |
D |
$292.85 |
$1,024,389 |
D/D |
(3,498) |
68,986 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$713,548 |
D/D |
(2,468) |
66,518 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-08-03 |
4 |
AS |
$276.96 |
$540,137 |
D/D |
(1,941) |
35,103 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-05-11 |
4 |
AS |
$276.25 |
$3,014,014 |
D/D |
(10,665) |
35,103 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-05-06 |
4 |
AS |
$275.28 |
$184,162 |
D/D |
(669) |
35,103 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-05-15 |
4 |
AS |
$274.67 |
$16,496 |
D/D |
(58) |
35,103 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-05-05 |
4 |
AS |
$265.72 |
$3,606,232 |
D/D |
(13,356) |
35,103 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-05-04 |
4 |
AS |
$258.59 |
$11,475,179 |
D/D |
(43,752) |
35,103 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-02-11 |
4 |
AS |
$243.53 |
$3,216,311 |
D/D |
(13,070) |
46,198 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-02-18 |
4 |
AS |
$242.04 |
$849,780 |
D/D |
(3,489) |
39,447 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$787,773 |
D/D |
(3,262) |
42,936 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$2,943,204 |
D/D |
(12,215) |
59,268 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
